PACAP 1-38 as an inhaled bronchodilator in guinea pigs in vivo

Peptides. 1998;19(1):93-8. doi: 10.1016/s0196-9781(97)00256-8.

Abstract

The effect on total pulmonary resistance (R1) was examined for inhaled PACAP 1-38, PACAP 1-27 and VIP in anesthetized, ventilated guinea pigs. Two minutes after inhalation, PACAP 1-38 (36 +/- 6%), PACAP 1-27 (42 +/- 9%) and VIP (48 +/- 19%) inhibited the increase in R1 (% inhibition of histamine-induced R1 prior to inhalation) caused by histamine i.v., whereas the vehicle (-1 +/- 10%) did not. This inhibitory effect lasted five times longer for PACAP 1-38 (> 50 min) than for PACAP 1-27 and VIP (< 10 min). The inhaled peptides caused no sustained effects on heart rate or blood pressure. Infusion of PACAP 1-38 i.v. dose-dependently inhibited the increase in R1 caused by inhaled histamine and by carbachol i.v..

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Inhalation
  • Airway Resistance / drug effects*
  • Animals
  • Blood Pressure / drug effects
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / pharmacology*
  • Carbachol / pharmacology
  • Guinea Pigs
  • Heart Rate / drug effects
  • Histamine / pharmacology
  • Lung / drug effects*
  • Male
  • Neuropeptides / administration & dosage
  • Neuropeptides / pharmacology*
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / pharmacology*
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Vasoactive Intestinal Peptide / administration & dosage
  • Vasoactive Intestinal Peptide / pharmacology*

Substances

  • Bronchodilator Agents
  • Neuropeptides
  • Peptide Fragments
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • pituitary adenylate cyclase-activating-peptide (1-38), pig
  • Vasoactive Intestinal Peptide
  • Histamine
  • Carbachol